Drug Profile


Alternative Names: Bestrabucil; Busramustine; KM 2210; Kregan

Latest Information Update: 09 Jan 1995

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kureha Corporation
  • Class Antineoplastics
  • Mechanism of Action DNA inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Graft-versus-host disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 09 Jan 1995 Discontinued-Preclinical for Graft-versus-host disease in Japan (Unknown route)
  • 07 Nov 1994 Discontinued-preregistration for Breast cancer in Japan (PO)
  • 07 Nov 1994 Discontinued-preregistration for Non-Hodgkin's lymphoma in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top